Scott Kathleen D., CFO of ARS Pharmaceuticals ($SPRY), made two open market sales totaling $893,000 in the last year. Her latest sale occurred on August 21, 2025. These transactions rank 5,198th among 11,678 individual insiders, below the average of $8.6 million and 6.4 sales per insider. She reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | Dermata Therapeutics, Inc. | $DRMA | Scott Kathleen D. | Director | A | Stock Option (Right to Buy) | 2500 | $0.00 | 2,500.0000 | 1,026,457 | 9999.99% | 0.24% |
| Jan. 2, 2026 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | A | Stock option (right to buy) | 240000 | $0.00 | 240,000.0000 | 98,807,600 | 9999.99% | 0.24% |
| Aug. 21, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | S | Common Stock | 12500 | $15.00 | 18,292.0000 | 102,390,828 | 40.59% | 0.01% |
| Aug. 21, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | M | Common Stock | 12500 | $1.50 | 30,792.0000 | 102,390,828 | 68.34% | 0.01% |
| Aug. 21, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | M | Stock Option (Right to Buy) | 12500 | $0.00 | 739,830.0000 | 102,390,828 | 1.66% | 0.01% |
| May 20, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | M | Common Stock | 50000 | $1.50 | 65,674.0000 | 102,390,828 | 319.00% | 0.05% |
| May 20, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | S | Common Stock | 50000 | $14.10 | 15,674.0000 | 102,390,828 | 76.13% | 0.05% |
| May 20, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | M | Stock Option (Right to Buy) | 50000 | $0.00 | 752,330.0000 | 102,390,828 | 6.23% | 0.05% |
| Jan. 13, 2025 | Dermata Therapeutics, Inc. | $DRMA | Scott Kathleen D. | Not found | A | Stock Option (Right to Buy) | 5000 | $0.00 | 5,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 2, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | A | Stock option (right to buy) | 176700 | $0.00 | 176,700.0000 | 102,390,828 | 9999.99% | 0.17% |
| Dec. 6, 2024 | NKGen Biotech, Inc. | $NKGN | Scott Kathleen D. | Director | A | Stock Option (right to buy) | 300000 | $0.00 | 300,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 6, 2024 | NKGen Biotech, Inc. | $NKGN | Scott Kathleen D. | Director | A | Stock Option (right to buy) | 500000 | $0.00 | 500,000.0000 | 0 | 9999.99% | 0.00% |
| Oct. 16, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | M | Stock Option (Right to Buy) | 12500 | $0.00 | 802,330.0000 | 97,032,331 | 1.53% | 0.01% |
| Oct. 16, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | S | Common Stock | 12500 | $16.00 | 13,199.0000 | 97,032,331 | 48.64% | 0.01% |
| Oct. 16, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | M | Common Stock | 12500 | $1.50 | 25,699.0000 | 97,032,331 | 94.70% | 0.01% |
| Aug. 20, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | S | Common Stock | 12500 | $16.00 | 13,199.0000 | 95,215,322 | 48.64% | 0.01% |
| Aug. 20, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | M | Common Stock | 12500 | $1.50 | 25,699.0000 | 95,215,322 | 94.70% | 0.01% |
| Aug. 20, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | M | Stock Option (Right to Buy) | 12500 | $0.00 | 814,830.0000 | 95,215,322 | 1.51% | 0.01% |
| Feb. 12, 2024 | NKGen Biotech, Inc. | $NKGN | Scott Kathleen D. | Director | A | Stock Option (right to buy) | 300000 | $0.00 | 300,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 4, 2024 | Dermata Therapeutics, Inc. | $DRMA | Scott Kathleen D. | Not found | A | Stock Option (Right to Buy) | 10000 | $0.00 | 10,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 2, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | A | Stock option (right to buy) | 200000 | $0.00 | 200,000.0000 | 95,215,322 | 9999.99% | 0.21% |
| Jan. 3, 2023 | ARS Pharmaceuticals, Inc. | $SPRY | Scott Kathleen D. | Chief Financial Officer | A | Stock option (right to buy) | 50000 | $0.00 | 50,000.0000 | 0 | 9999.99% | 0.00% |